Share Facebook Twitter LinkedIn Pinterest Email Spero Therapeutics GAAP EPS of $0.96 beats by $1.06, revenue of $73.5M beats by $54.87M
Tko targets 2026 revenue of $5.775B-$5.825B while raising adjusted EBITDA outlook to $2.275B-$2.305B (NYSE:TKO)August 4, 2026